MAURI MARIO
- U08, Floor: 4, Room: 4039
Publications
Elli, E., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., et al. (2024). Idiopathic erythrocytosis: a germline disease?. CLINICAL AND EXPERIMENTAL MEDICINE, 24(1) [10.1007/s10238-023-01283-y]. Detail
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Detail
Cordani, N., Mologni, L., Piazza, R., Tettamanti, P., Cogliati, V., Mauri, M., et al. (2023). TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(22) [10.3390/ijms242216294]. Detail
Difrancesco, J., Ragona, F., Murano, C., Frosio, A., Melgari, D., Binda, A., et al. (2023). A novel de novo HCN2 loss-of-function variant causing developmental and epileptic encephalopathy treated with a ketogenic diet. EPILEPSIA, 34(12 (December 2023)), 222-228 [10.1111/epi.17777]. Detail
Cordani, N., Lisini, D., Coccè, V., Paglia, G., Meanti, R., Cerrito, M., et al. (2023). Conditioned Medium of Mesenchymal Stromal Cells Loaded with Paclitaxel Is Effective in Preclinical Models of Triple-Negative Breast Cancer (TNBC). INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 24(6), 1-16 [10.3390/ijms24065864]. Detail